Collaborations
Anaveon is open for collaborations with biotechnology, pharmaceutical, and other therapeutics partners to discover, develop and commercialize innovative treatments in the fields of oncology (including immuno-oncology) and immune-related disorders. We welcome opportunities to partner through in- and out-licensure, co-development, region-specific agreements, joint ventures, and other collaborations.
Our company’s strengths include:
Innovation
- cutting-edge science with a tailored approach and a focus on biologic therapeutics and immunology
Speed
- rapid execution from drug design and discovery through preclinical and clinical development
Experience
- cross-functional team with decades of experience with multiple indications in large pharma, specialty therapeutics and entrepreneurial biotechs
Operations
- in-house laboratories, CMC development expertise, and broad clinical strategy and operations capabilities
Excellence
- world-renowned scientific advisors, top-tier investors, quality heritage, honest and collaborative values
If you wish to learn more about collaborating with Anaveon, please contact us:
Anaveon has entered into a clinical trial collaboration and supply agreement with MSD, to evaluate Anaveon’s wholly-owned drug candidate ANV600 in combination with KEYTRUDA in clinical trials. Under the terms of the agreement, MSD will supply KEYTRUDA. Anaveon retains all worldwide rights to ANV600.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.